18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques

摘要: The aim of the present study was to investigate if 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) outperforms conventional imaging techniques for excluding distant metastases prior neoadjuvant chemotherapy (NAC) treatment in patients with stage II and III breast cancer. Second, we assessed clinical importance false positive findings. One hundred fifty four or cancer, scheduled receive NAC, underwent an 18F-FDG PET/CT scan imaging, consisting bone scintigraphy, ultrasound liver, chest radiography. Suspect additional lesions at staging examination were confirmed by biopsy histopathology and/or imaging. Metastases that detected within 6 months after considered evidence occult metastasis, missed examination. Forty-two seen 25 could be 20 (13%) 154 patients. 8 (19%) misclassified presence metastatic disease 5 (3%) In 16 (80%) patients, exclusively PET/CT, leading a change 13 (8%) 129 negative no developed during follow-up 9.0 months. Sensitivity, specificity, predictive value, accuracy detection cancer are 100, 96, 80, 97%, respectively. FDG is superior untreated associated low rate. may value NAC.